Every 8-K that RenovoRx, Inc. (RNXT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RNXT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNXT filings page.
RenovoRx, Inc. (RNXT) reports that its common stock has regained compliance with Nasdaq’s Minimum Bid Price Requirement under Listing Rule 5550(a)(2). The company previously received notice of non-compliance on December 31, 2025, after its closing bid price remained below $1.00 per share for 30 consecutive business days.
Nasdaq informed RenovoRx on August 20, 2026 that, for the ten consecutive business days from August 6, 2026 through August 19, 2026, the closing bid price of its common stock was $1.00 per share or greater. As a result, RenovoRx is now back in compliance with the Nasdaq minimum bid price standard and Nasdaq considers the matter closed.
RenovoRx, Inc. reported record Q2 2026 revenue of $909,000, up approximately 61% from Q1 2026 and 115% from Q2 2025, driven by accelerating commercial adoption of its FDA-cleared RenovoCath device. Gross profit was $766,000, yielding an approximately 84% gross margin.
Net loss for the quarter was $2.9 million, similar to the prior year, as the company increased selling, general and administrative spending to build commercial infrastructure. Cash and cash equivalents totaled $9.5 million as of June 30, 2026, which the company believes will fund operations into the second half of 2027.
RenovoRx raised its 2026 revenue guidance to $3.75–$4.25 million, implying approximately 241%–286% growth over 2025. The company ended the quarter with 21 active commercial cancer center customers and a total commercial funnel of 63 centers. Its Phase III TIGeR-PaC trial reached full enrollment, with trial completion expected in the first half of 2027 and topline data in the second half of 2027.
RenovoRx, Inc. reported record second quarter 2026 results, with revenue of $909,000, up approximately 61% from the first quarter of 2026 and 115% from the prior-year quarter. For the first six months of 2026, revenue totaled $1.47 million, and second-quarter revenue alone represented about 83% of full-year 2025 revenue.
Gross profit was $766,000, for a gross margin of about 84%. The company recorded a net loss of $2.9 million, similar to a year earlier, and ended June 30, 2026 with $9.5 million in cash and cash equivalents, which it believes funds operations into the second half of 2027. Active commercial cancer center customers reached 21, with a total commercial funnel of 63 centers.
RenovoRx increased its 2026 revenue guidance to a range of $3.75–$4.25 million, implying approximately 241%–286% growth over 2025. The Phase III TIGeR-PaC trial of intra-arterial gemcitabine via RenovoCath has reached full enrollment, with completion expected in the first half of 2027 and topline data in the second half of 2027.
RenovoRx, Inc. is highlighting its oncology platform and clinical program through participation in a JonesTrading key opinion leader webinar on August 13, 2026, focused on pancreatic cancer and the company’s Trans-Arterial Micro-Perfusion (TAMP™) platform and RenovoCath® device.
The company reports that its first full year of commercial efforts in 2025 generated approximately $1.1 million in RenovoCath sales and a record $563,000 of sales in the first quarter of 2026. RenovoRx is evaluating intra-arterial gemcitabine delivered via RenovoCath in the ongoing Phase III TIGeR-PaC trial and states it anticipates full enrollment in the very near term and final data readout in mid to late 2027. The IAG combination product candidate remains investigational and not approved for commercial sale, while RenovoCath with gemcitabine has Orphan Drug Designation, which would provide seven years of market exclusivity upon potential FDA new drug application approval.
RenovoRx, Inc. reported that Nasdaq has granted it a second 180-day period, until December 28, 2026, to regain compliance with the exchange’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
To regain compliance during this second period, the company’s common stock must close at or above $1.00 per share for at least 10 consecutive business days, after which Nasdaq would issue written confirmation. If RenovoRx does not meet this standard by the new deadline, Nasdaq will notify the company that its common stock will be delisted, though RenovoRx would then have the opportunity to appeal the determination to a Nasdaq Hearings Panel.
RenovoRx, Inc. held its 2026 annual meeting of stockholders, with a quorum of about 22,825,465 shares present out of 45,052,706 shares entitled to vote as of May 11, 2026. Stockholders elected all seven director nominees to one-year terms, each receiving over 12.8 million votes.
Stockholders also approved an amendment to the Amended and Restated 2021 Omnibus Equity Incentive Plan, adding 2,000,000 shares of common stock, equal to 4.4% of total issued and outstanding shares, to the shares reserved for issuance under the plan (9,666,218 votes for, 3,565,088 against).
In addition, stockholders ratified the appointment of Frank, Rimerman + Co. LLP as independent registered public accounting firm for the year ending December 31, 2026, with 21,938,316 votes for, 477,181 against, and 409,966 abstentions.
RenovoRx reported record first quarter 2026 results, with revenue of $563,000, up 136% from the fourth quarter of 2025 as adoption of its RenovoCath device and TAMP therapy platform increased across U.S. cancer centers.
Gross margin improved to 85.1%. The company posted a net loss of $3.5 million and non-GAAP net loss of $3.2 million, reflecting higher selling, general and administrative spending to build commercial infrastructure while research and development costs declined. RenovoRx ended the quarter with $12.4 million in cash and completed an oversubscribed private placement raising about $10 million, which management believes will fund operations into at least the second half of 2027.
The commercial footprint expanded to 16 active cancer center customers as of May 6, 2026, with 32 additional centers in the pipeline and a target of 36 active centers by year-end 2026. The Phase III TIGeR-PaC trial for locally advanced pancreatic cancer reached 106 of 114 required randomized patients and 74 of 86 required events, with full enrollment expected by the end of June 2026 and final data anticipated in mid to late 2027. Management reiterated full-year 2026 revenue guidance of $3–$4 million.
RenovoRx reported full-year 2025 results and a business update. Revenue rose to $1.1 million from $43,000 in 2024, reflecting the first full year of RenovoCath commercialization across U.S. cancer centers. Net loss widened to $11.2 million from $8.8 million as the company invested in its Phase III TIGeR-PaC trial and commercial buildout.
Cash and cash equivalents were $7.0 million at December 31, 2025, and an oversubscribed March 2026 private placement added $10 million in gross proceeds, leaving about $13 million on hand. As of March 24, 2026, the TIGeR-PaC trial had randomized 104 patients with 72 events toward a 114-patient, 86-event target, and 12 cancer centers were actively using RenovoCath with additional centers in the pipeline.
RenovoRx, Inc. appointed Ramtin Agah, M.D., its Chief Medical Officer and Board Chairman, to the newly created role of Executive Chairman, effective February 27, 2026. An offer letter dated March 24, 2026 sets his annualized base salary at $450,000 for at least 30 hours per week.
Dr. Agah is eligible for a discretionary annual bonus of up to 40% of his base salary, with the first bonus payable in 2027 for 2026 performance. He may also receive annual stock options and other equity awards under the 2021 Omnibus Equity Incentive Plan, subject to vesting and continued service. His employment is at will and includes customary confidentiality and intellectual property provisions.
RenovoRx, Inc. entered into a private placement with 15 accredited and institutional investors, including company insiders, raising approximately $10 million in gross proceeds. The company sold 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and revenue milestone warrants for 5,319,392 shares.
Institutional investors paid $0.938 per share and related milestone warrant, while insiders paid $1.0288 to comply with Nasdaq rules. The milestone warrants are immediately exercisable at $1.751 per share for institutions and $1.9326 for insiders, and expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for a quarter.
RenovoRx agreed to file and seek effectiveness of a resale registration statement for the shares and warrant shares within specified timelines, with cash liquidated damages of up to 10% of each investor’s subscription amount if deadlines are missed. The company plans to use proceeds to support commercialization of its RenovoCath device and advance its Phase III TIGeR-PaC trial.
RenovoRx, Inc. announced leadership changes in its finance organization and highlighted early commercial traction for its RenovoCath device. Principal Accounting Officer Ronald B. Kocak resigned from that role on February 3, 2026, but remains Vice President and Controller with his 2026 salary unchanged.
On February 4, 2026, the board appointed consultant Mark Voll as Chief Financial Officer, serving as the company’s principal financial and accounting officer. Under a consulting agreement, he is paid $250 per hour, half in cash and half in restricted stock units, and is eligible for an initial grant of 60,000 RSUs under the 2021 Omnibus Equity Incentive Plan. A related press release notes that RenovoRx generated approximately $900,000 of RenovoCath sales revenue in the first nine months of 2025 as it transitions from purely clinical-stage activities toward commercialization.
RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing it to issue and sell up to $3,723,029 of common stock from time to time in at-the-market offerings or negotiated transactions. JonesTrading will act as sales agent or principal and may receive a commission of up to 3.0% of the gross sales price of any shares sold. The shares will be offered under RenovoRx’s existing Form S-3 shelf registration statement, and a newly filed Form S-3 allows continued use of that shelf for an additional 180 days past its November 21, 2025 expiration.
RenovoRx (RNXT) furnished an update via an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The company also included updates on its clinical trial and commercialization strategy as described in the press release.
The press release is attached as Exhibit 99.1 and incorporated by reference. RNXT’s common stock trades on the Nasdaq Capital Market under the symbol RNXT.
RenovoRx, Inc. filed a current report stating that on August 14, 2025 it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company also used the press release to share updates on its clinical trial and commercialization strategy.
The press release is included as Exhibit 99.1 to the report and is incorporated by reference, meaning the detailed financial figures and strategic updates are provided in that exhibit rather than in the body of the report.
RenovoRx, Inc. (Nasdaq: RNXT) filed a Form 8-K to report the voting results of its 2025 Annual Meeting held on 24 June 2025. Of the 36,551,752 shares outstanding on the 25 April 2025 record date, approximately 20,086,518 shares (55%) were present or represented by proxy, satisfying quorum requirements.
Proposal 1 – Director Elections: All seven nominees were elected to one-year terms expiring at the 2026 meeting. Four directors (Bagai, Agah, Macfarlane) received ~13.0 million votes each with minimal withholds, while three directors (Marton, Ryan, Spiegel) received ~9.5-9.9 million votes and ~3.3-3.6 million withholds. Broker non-votes were 6.95 million for every nominee.
Proposal 2 – Equity Incentive Plan Amendments: Shareholders approved (i) reserving an additional 913,794 shares (2.5% of outstanding) for the 2021 Omnibus Equity Incentive Plan and (ii) raising the plan’s evergreen provision from 3% to 5% of year-end shares. Votes: 9,056,181 for; 4,037,698 against; 38,379 abstentions; 6,954,260 broker non-votes.
Proposal 3 – Auditor Ratification: Frank, Rimerman + Co. LLP was ratified as independent auditor for FY 2025 with strong support (19,131,750 for; 949,070 against; 5,698 abstentions).
The filing discloses no financial performance metrics or strategic transactions but confirms routine corporate governance matters, an expanded share reserve for equity compensation, and continuity of external audit oversight.